Patients Whose First Episode of Bleeding Occurs While Taking a β-Blocker Have High Long-term Risks of Rebleeding and Death

Clinical Gastroenterology and Hepatology

Volumn 10, Issue 6, 2012, Pages 670-676

  de Souza, Andrea Ribeiro ^a,b   La Mura, Vincenzo ^a,b   Reverter, Enric ^a,b   Seijo, Susana ^a,b   Berzigotti, Annalisa ^a,b   Askenazhi, Eyal ^a,b   García Pagán, Juan Carlos ^a,b   Abraldes, Juan G ^a,b   Bosch, Jaime ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Clinical Trial; Drug; Portal Hypertension; Propranolol

Indexed keywords

BILIRUBIN; NADOLOL; PROPRANOLOL;

ADULT; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; CHILD PUGH CLASSIFICATION; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG DOSE INCREASE; ENDOSCOPIC BAND LIGATION; ENDOSCOPIC THERAPY; ESOPHAGUS VARICES BLEEDING; FEMALE; FOLLOW UP; HUMAN; LIGATION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; POST TREATMENT SURVIVAL; PRIMARY PREVENTION; PROGNOSIS; SECONDARY PREVENTION;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ESOPHAGEAL DISEASES; FEMALE; HEMORRHAGE; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RECURRENCE; RISK ASSESSMENT; SPAIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84861333905     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.02.011     Document Type: Article

References (27)

1. Garcia-Tsao G., Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med 2010, 362:823-832.
2. Graham D., Smith J. The course of patients after variceal hemorrhage. Gastroenterology 1981, 80:800-806.
3. Bosch J., García-Pagán J.C. Prevention of variceal rebleeding. Lancet 2003, 361:952-954.
4. Bosch J., Berzigotti A., Garcia-Pagan J.C., et al. The management of portal hypertension: rational basis, available treatments and future options. J Hepatol 2008, 48(Suppl 1):S68-S92.
5. Thalheimer U., Bosch J., Burroughs A.K. How to prevent varices from bleeding: shades of grey-the case for nonselective beta blockers. Gastroenterology 2007, 133:2029-2036.
6. Feu F., García-Pagán J.C., Bosch J., et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995, 346:1056-1059.
7. Abraldes J.G., Tarantino I., Turnes J., et al. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology 2003, 37:902-908.
8. D'Amico G., Garcia-Pagan J.C., Luca A., et al. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology 2006, 131:1611-1624.
9. de Franchis R., Baveno V.Faculty Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2010, 53:762-768.
10. Bureau C., Péron J.M., Alric L., et al. "A la carte" treatment of portal hypertension: adapting medical therapy to hemodynamic response for the prevention of bleeding. Hepatology 2002, 36:1361-1366.
11. Garcia-Tsao G., Sanyal A.J., Grace N.D., et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007, 46:922-938.
12. García-Pagán J.C., Villanueva C., Albillos A., et al. Nadolol plus isosorbide mononitrate alone or associated with band ligation in the prevention of recurrent bleeding: a multicenter randomized controlled trial. Gut 2009, 58:1144-1150.
13. Kumar A., Jha S.K., Sharma P., et al. Addition of propranolol and isosorbide mononitrate to endoscopic variceal ligation does not reduce variceal rebleeding incidence. Gastroenterology 2009, 137:892-901.
14. Lo G.H., Lai K.H., Cheng J.S., et al. Endoscopic variceal ligation plus nadolol and sucralfate compared with ligation alone for the prevention of variceal rebleeding: a prospective, randomized trial. Hepatology 2000, 32:461-465.
15. De la Peña J., Brullet E., Sanchez-Hernández E., et al. Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding: a multicenter trial. Hepatology 2005, 41:572-578.
16. Lo G.H., Chen W.C., Chan H.H., et al. A randomized, controlled trial of banding ligation plus drug therapy versus drug therapy alone in the prevention of esophageal variceal rebleeding. J Gastroenterol Hepatol 2009, 24:982-987.
17. Satagopan J.M., Ben-Porat L., Berwick M., et al. A note on competing risks in survival data analysis. Br J Cancer 2004, 91:1229-1235.
18. Gray R.J. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988, 16:1141-1154.
19. Fine J.P., Gray R.J. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999, 94:496-509.
20. Malinchoc M., Kamath P.S., Gordon F.D., et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000, 31:864-871.
21. Villanueva C., Balanzó J., Novella M.T., et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med 1996, 334:1624-1629.
22. Villanueva C., Miñana J., Ortiz J., et al. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med 2001, 345:647-655.
23. González A., Augustin S., Pérez M., et al. Hemodynamic response-guided therapy for prevention of variceal rebleeding: an uncontrolled pilot study. Hepatology 2006, 44:806-812.
24. Bosch J. Carvedilol for portal hypertension in patients with cirrhosis. Hepatology 2010, 51:2214-2218.
25. Bañares R., Moitinho E., Matilla A., et al. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology 2002, 36:1367-1373.
26. Vorobioff J., Groszmann R.J., Picabea E., et al. Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study. Gastroenterology 1996, 111:701-709.
27. Muntaner L., Altamirano J.T., Augustin S., et al. High doses of beta-blockers and alcohol abstinence improve long-term rebleeding and mortality in cirrhotic patients after an acute variceal bleeding. Liver Int 2010, 30:1123-1130.